BeiGene’s Q3 2024 Results Show 28% YOY Revenue Growth Driven by Brukinsa and Tevimbra
BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a China-based biotech company, has released its...
Finanical Reports
Bayer AG Posts Modest Q3 Growth with Strong Performance from New Pharmaceuticals
Germany-based Bayer AG (ETR: BAYN) has released its Q3 2024 financial results, reporting a 0.6%...
Zai Lab Ltd Reports 46% YOY Revenue Growth in Q3 2024 Driven by Vygart, Zejula, and Nuzyra
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has released its Q3 2024 financial...
Legend Biotech’s Q3 Revenue Soars 67% YOY Driven by Carvykti Sales
China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced its financial results for the third quarter...
InnoCare Pharma Reports 29.8% Revenue Increase in Q3 2024 Financials
Beijing-based biotech InnoCare Pharma (HKG: 9969; SHA: 688428) has released its financial report for the...
Viatris Reports Q3 2024 Global Sales of USD 3.8 Billion with a 5% YOY Decline
US generics giant Viatris (NASDAQ: VTRS) has published its financial report for the third quarter...
Gilead Sciences Reports 7% YOY Increase in Q3 2024 Product Sales, Driven by HIV Therapies
Gilead Sciences Inc., (NASDAQ: GILD), a major US-based pharmaceutical company, has released its financial results...
Novo Nordisk Reports Q3 2024 Financials with 24% YOY Revenue Growth
Denmark-based pharmaceutical company Novo Nordisk A/S (NYSE: NVO) has released its financial results for the...
Siemens Healthineers AG Reports Fiscal 2024 Results with Targeted Revenue Growth
Germany-based medical device giant Siemens Healthineers AG (ETR: SHL) has released its financial results for...
Fresenius Medical Care Reports 2% YOY Revenue Decrease in 2024 Q3 Financial Results
Germany-based Fresenius Medical Care (FRA: FMEA) has released its financial report for the third quarter...
Takeda Reports 5% YOY Revenue Growth and Upgrades Forecasts for Fiscal 2024
Takeda (TYO: 4502) has released its earnings results for the first half of fiscal year...
MSD Reports 4% YOY Revenue Increase in Q3 2024, Led by Pharmaceutical Sector
US pharmaceutical giant Merck, Sharp & Dohme Inc., (MSD; NYSE: MRK) has released its financial...
Regeneron Pharmaceuticals Reports 11% YOY Revenue Growth in Q3 2024
US-based Regeneron Pharmaceuticals (NASDAQ: REGN) has reported its financial details for the third quarter of...
Biogen Reports Q3 2024 Sales Dip, Raises Full-Year Guidance
US biotechnology company Biogen Inc. (NASDAQ: BIIB) reported global sales of USD 2.466 billion for...
Innovent Biologics Reports Q3 2024 Sales Exceeding RMB 2.3 Billion, Up 40% YOY
China-based Innovent Biologics Inc., (HKG: 1801) has announced product sales exceeding RMB 2.3 billion (USD...
Dizal Pharmaceutical’s Q3 2024 Revenues Soar 236% YOY on Strong Product Sales
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has released its financial report for the third...
Amgen Reports Q3 2024 Revenues of USD 8.5 Billion, Marking a 23% YOY Increase
US biotechnology company Amgen (NASDAQ: AMGN) has announced its financial results for the third quarter...
Sandoz Q3 2024 Sales Boosted by Biosimilars and Generics, Up 12% YOY
Switzerland-based Sandoz (SWX: SDZ) has published its financial statements for the third quarter of 2024,...
Junshi Biosciences Reports Q3 2024 Financials with Revenue Growth and Narrowed Losses
Junshi Biosciences (HKG: 1877; SHA: 688180) has released its financial results for the third quarter...
Eli Lilly Reports 20% YOY Revenue Growth in Q3 2024 Driven by Mounjaro and Zepbound
US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has reported its financial results for...